



Steven H. Collis
Chairman, President & CEO
AmerisourceBergen Corporation
227 Washington Street
Conshohocken, PA 19428
610-727-7000 Phone
www.amerisourcebergen.com

As you may be aware, ABC recently entered into criminal and civil resolutions with the United States and individual states in connection with ABC's conduct relating to the preparation and distribution of syringes that were pre-filled with oncology supportive care drugs. This letter provides you with additional information about the settlements, explains ABC's commitments going forward, and provides you with access to information about those commitments.

The Government alleges that ABC engaged in several types of unlawful and improper conduct relating to a pre-filled syringe program based at a Dothan, Alabama facility. More specifically, the United States contends that ABC and its subsidiaries, through the pre-filled syringe program, caused the submission of numerous false claims to Federal health care programs.

To address criminal liability associated with the pre-filled syringe program, a subsidiary of ABC pled guilty to violating the Federal Food Drug, and Cosmetic Act and agreed to pay \$260 million in criminal penalties. In addition, the federal government and several individual states alleged that ABC's conduct violated the Federal False Claims Act and equivalent state statutes. To resolve those allegations, ABC entered into a separate civil False Claims Act settlement in which ABC agreed to pay the United States and participating states \$625 million. More information about the criminal plea and civil settlement may be found at the following:

<https://www.justice.gov/usao-edny/pr/amerisourcebergen-specialty-group-pleads-guilty-distributing-misbranded-drugs-and>

<https://www.justice.gov/opa/pr/amerisourcebergen-corporation-agrees-pay-625-million-resolve-allegations-it-illegally>

As part of the settlement, ABC also entered into a five-year corporate integrity agreement with the Office of Inspector General of the U.S. Department of Health and Human Services. The corporate integrity agreement is available at <http://oig.hhs.gov/fraud/cia/index.html>. Under this agreement, ABC agreed to maintain and undertake certain obligations designed to promote compliance with Federal health care program, FDA, and DEA requirements. We also agreed to notify healthcare providers about the settlement and inform them that they can report any questionable practices by ABC's representatives to ABC's Compliance organization or the FDA using the information set out below.

Please call ABC at (833) 247-2760 or email us at OOC@amerisourcebergen.com if you have questions about the settlement referenced above. Please call ABC at (833) 247-2760 or email us at OOC@amerisourcebergen.com to report any instances in which you believe that a ABC representative engaged in questionable conduct. If you wish to remain anonymous, please call (800) 570-4810 or report online at <http://www.tnwgrc.com/Amerisourcebergen>. Alternatively, you may report any improper conduct associated with prescription drug marketing to the FDA's Office of Prescription Drug Promotion at 301-796-1200.

A handwritten signature in black ink, appearing to read "Sh H Collis", written over a light blue horizontal line.

Steven H. Collis
Chairman, President and Chief Executive Officer